UK approves its first CRISPR-edited crop to tackle livestock methane

Summary

The UK has officially greenlit its first gene-edited crop, marking a major departure from the strict agricultural regulations long enforced by the European Union. Under a new set of rules for precision breeding, plants that have been tweaked using tools like CRISPR face minimal oversight as long as the genetic changes could have theoretically occurred in nature or through traditional breeding. This means scientists can make precise, beneficial adjustments without introducing foreign DNA into the plant.

The first crop to clear this new regulatory hurdle is a specialized strain of barley developed by Rothamsted Research, an agricultural center in England. Scientists used CRISPR, a powerful technology that acts like molecular scissors, to silence two specific genes called SDP1A and SDP1B. Normally, these genes produce enzymes that break down natural oils in the plant. By disrupting them, researchers allow the barley to store up much higher levels of fats, known as lipids, in its leaves and stems.

Why it matters.

This approval is a landmark moment that could kick off a new era of crop innovation in the UK, making it easier and faster for scientists to develop plants that solve specific agricultural problems. For the newly approved barley, the extra fat content provides a much richer source of energy for grazing livestock like cows and sheep. More importantly, feeding animals these lipid-rich plants has the potential to reduce the amount of methane they produce during digestion, offering a creative strategy to curb a potent greenhouse gas.

However, it is important to recognize that this project is still in its early stages. While the regulatory breakthrough is significant, the environmental benefits remain largely theoretical right now. Researchers still need robust field trial data to prove how well this modified barley will grow on a commercial scale and to quantify exactly how much methane it can actually eliminate on real-world farms.

From the source

The story in numbers.

UK regulatory approval for a gene-edited crop: 1st
Genes disrupted (SDP1A and SDP1B): 2

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

Follow your curiosity.

UK approves its first CRISPR-edited crop to tackle livestock methane

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

Summary

Why it matters.

The story in numbers.

Follow the evidence.

Your next discovery.

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

FDA shakeups, safety warnings, and a promising obesity pill

Physical decline starts at 35, but late-in-life exercise boosts fitness

A little science goes a long way.